What is HC Wainwright’s Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Neurogene in a report released on Monday, May 18th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($1.43) per share for the quarter. The consensus estimate for Neurogene’s current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2027 earnings at ($1.45) EPS, Q3 2027 earnings at ($1.49) EPS and Q4 2027 earnings at ($1.55) EPS.

NGNE has been the subject of a number of other reports. Guggenheim began coverage on shares of Neurogene in a report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price objective for the company. Lifesci Capital initiated coverage on Neurogene in a research report on Monday, January 26th. They issued an “outperform” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group lowered their price objective on Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Neurogene presently has a consensus rating of “Moderate Buy” and an average price target of $74.17.

Neurogene Trading Down 6.2%

Neurogene stock opened at $27.98 on Tuesday. The company has a market capitalization of $442.14 million, a P/E ratio of -6.15 and a beta of 1.69. The firm’s fifty day simple moving average is $24.30 and its 200-day simple moving average is $22.06. Neurogene has a 1-year low of $14.65 and a 1-year high of $37.27.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09).

Insiders Place Their Bets

In related news, CFO Christine Mikail Cvijic sold 9,600 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00. Following the completion of the transaction, the chief financial officer owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the sale, the insider owned 30,497 shares of the company’s stock, valued at approximately $634,642.57. The trade was a 18.23% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 20,442 shares of company stock valued at $525,622. Company insiders own 11.64% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Balyasny Asset Management L.P. bought a new stake in shares of Neurogene in the third quarter valued at approximately $12,114,000. ArrowMark Colorado Holdings LLC raised its stake in Neurogene by 1.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock valued at $10,326,000 after purchasing an additional 10,442 shares during the last quarter. Jennison Associates LLC boosted its holdings in Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after purchasing an additional 138,999 shares during the period. State Street Corp increased its holdings in shares of Neurogene by 47.8% during the 4th quarter. State Street Corp now owns 307,797 shares of the company’s stock worth $6,341,000 after purchasing an additional 99,487 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Neurogene by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock valued at $5,145,000 after buying an additional 3,262 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.